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Abstract
Although the strong association between human papilloma virus (HPV) and 
cervical cancer has been widely demonstrated, it seems that uterine cervix cancer is 
not the only gynecologic malignancy induced by this pathogenic agent. It has been 
shown that HPV infection plays a central role in the development of vulvar cancer 
too, HPV 16 and 18 being the most frequently reported genotypes that might induce 
this kind of lesions. This aspect presents a particular importation, patients diag-
nosed with HPV-related vulvar cancer reporting a more favorable trend in regard 
with the long-term outcome. The current chapter aims to describe the pathogenesis 
as well as the therapeutic options and the long-term outcomes of patients in which 
association between HPV and vulvar cancer can be assessed.
Keywords: HPV, infection, squamous cell carcinoma, vulvar cancer, preneoplastic 
disease
1. Introduction
Discovering human papilloma virus (HPV) represented a crucial step in under-
standing and preventing the apparition of cervical cancer in women worldwide, the 
most frequently incriminated carcinogenic subtypes including HPV 16, 18, 31, 33, 
35, 39, 45, 51, 52, 56, 58, 59 [1]. However, it has been demonstrated that HPV infec-
tion plays a central role in the development of other malignancies such as vulvar, 
vaginal or anal cancer in women and anal or penile cancer in men [2].
2. The role of HPV in the development of premalignant vulvar lesions
Due to the fact that the incidence of vulvar squamous cell carcinoma has 
reported a continuous increase in the last decades, attention was focused on 
determining the pathogenesis of this lesion as well as on improving the therapeutic 
options [3, 4].
The main premalignant vulvar lesion consists of vulvar intraepithelial neoplasia 
(VIN), with an increasing incidence in the last decades; moreover, it seems that the 
age at diagnosis of this pathological feature has been consistently dropping in the 
last period of time, especially due to the relative increase of HPV infections [5, 6]. 
However, it seems that there are two different pathways leading to the apparition of 
this premalignant lesion; the first one is mainly related to type 16 HPV infection, 
while the second one is rather related to the presence of a nonneoplastic chronic 
inflammatory condition, lichen sclerosus [7, 8].
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Squamous cell carcinomas represent more than 90% of all vulvar cancer and are 
associated with several histopathological subtypes such as keratinized, basaloid warty 
or verrucous lesions; moreover, it seems that basaloid and warty lesions are more 
commonly seen in younger women, being usually associated with HPV DNA positiv-
ity. Contrarily, keratinized lesions that usually develop from chronic dermatoses such 
as lichen sclerosus are not associated with HPV infection and develop in older patients 
[9]. In cases associated with lichen sclerosus, the premalignant disease is usually 
referred as differentiated VIN (dVIN) [10]. A third category has been also proposed, 
comprising the VIN lesions, which could not be classified in either of the two above-
mentioned classes. This category is referred as VIN, unclassified type [11].
In order to study the clinicopathological characteristics of lichen-related vulvar 
carcinomas, Regauer et al. conducted a study on 38 patients diagnosed with this 
pathology [12]. Among these cases, 32 patients presented solitary lesions, while 
the remaining 6 patients presented multifocal lesions, all cases being HPV and p16 
negative. As for the stage of disease, inguinal metastases were present in 42% of 
cases at the time of presentation. When it comes to the performed therapy, radical 
surgery (consisting of radical resection with negative margins) was performed in 36 
cases, while the remaining 2 cases were submitted to radiochemotherapy. However, 
14 of the 36 surgically treated patients developed recurrent disease on the residual 
mucosa, 68% of them being diagnosed within the first year. Moreover, 14 of the 38 
patients died of the disease. In this way, the study came to demonstrate the strong 
association between the presence of lichen, the absence of HPV and a relatively 
poorer outcome of this class of patients [12].
In HPV-related lesions, it seems that the immune system of the host encounters 
a failure in order to produce an effective response to HPV; the longer time the HPV 
infection persists, the longer certain oncoproteins such as E6 or E7 will interfere 
with the cyclic cellular mechanisms, inducing cellular escape from the apoptotic 
process, and therefore malignant transformation [13, 14].
As for the VIN grading system, the first classification was proposed in 1986 
by the International Society for the Study of Vulvo-Vaginal Diseases and included 
the division of VIN in three grades [15]; two decades, later the same organization 
decided to change the grading system. Lesions that had been previously considered 
as VIN 1 have been regarded since that moment as warts or HPV infections, while 
VIN 2 and 3 have been generally referred as VIN [7, 15].
More recently, in order to provide a more specific classification, the Lower 
Anogenital Squamous Terminology Committee graded all the HPV-related tumors 
of the anogenital tract into two categories depending on the degree of differentia-
tion: the first category, LSIL (low-grade squamous intraepithelial lesions) refers to 
lesions presenting a lower grade of pathological transformation, while the second 
type of lesions HSIL (high-grade squamous intraepithelial lesions) refers to lesions 
with a higher grade of pathological transformation [16].
When it comes to the HPV-related VIN development, it seems that HPV DNA 
integration into the host cell genome plays a crucial role [17, 18]. An interesting 
study conducted on this theme was published by Peter Hillemanns and Xiuli Wang 
in Gynecologic Oncology in 2006 [19]. The study included 30 patients diagnosed 
with VIN at the University of Munich-Grosshaderm, Germany; among the 30 
patients, HPV DNA was detected in 25 women, the main identified subtypes 
including HPV 16 and HPV-18. The presence of HPV-16 or HPV-18 DNA was 
reported in eight cases, all of them being diagnosed with multicentric lesions of 
VIN, one of them also associating areas of vulvar carcinoma. Therefore, the authors 
concluded that the integration of HPV-DNA in the hosts presents a central role 
when it comes to the progression of the vulvar lesions to advanced or multifocal 
VIN lesions or even vulvar carcinomas [19].
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3. Epidemiology of HPV-related vulvar neoplasms
A recent study regarding the epidemiology of HPV-related vulvar neoplasms 
originates from the National Cancer Institute, Bethesda MD, United States of 
America, and was conducted by Brinton et al. [20]. The study was conducted on 
201,469 women, 370 of them being diagnosed with vulvar neoplasms including 
198 cases with grade 3 vulvar intraepithelial neoplasms. The mean age at the time 
of conducting the study was 61.8 years; among these cases, most patients were 
white, married, with a high level of education and parous. Moreover, a significant 
number of cases had been previously submitted to hysterectomy or reported a 
chronic usage of oral contraceptives or menopausal hormones, while more than 
one quarter of patients were obese. After a mean follow-up interval of 13.8 years, 
170 cases developed vulvar cancer (the mean age at diagnosis being 71 years), 
while 198 cases developed grade 3 vulvar intraepithelial neoplasia (at a mean age 
of 67.5 years). Demographic risk factors included nonwhite women, as well as the 
marital status (divorced or separated women reporting a significantly higher risk of 
development of the disease); however, the educational status did not influence the 
risk of the development of any kind of vulvar lesions. As for the parity status, the 
risk of vulvar lesions was significantly decreased among women who had delivered. 
Moreover, patients with a previous history of hysterectomy reported a trend to a 
higher risk of vulvar neoplasm development, although this fact was not statisti-
cally significant. However, this difference was not found among cases submitted 
to a prior oophorectomy. When it comes to the relationship between the body mass 
index and the risk of developing vulvar lesions, obese patients (defined through a 
body mass index higher than 30 kg/m2) had a significantly higher risk of develop-
ing invasive vulvar cancer; however, this relationship could not be established 
for patients with vulvar intraepithelial neoplasms. As for other lifestyle factors, 
diabetes or alcohol consumption did not influence the risk of vulvar neoplasm 
development, but smoking constituted in a significant risk factor. In the meantime, 
administration of hormonal therapies or oral contraceptives was only associated 
with the risk of development of intraepithelial lesions and not with the apparition 
of vulvar invasive cancer. Moreover, smoking was a risk factor especially among 
patients with HPV-related diseases [20].
4. The influence of HPV infection on the overall prognostic in patients 
diagnosed with vulvar squamous cell carcinoma
Although vulvar squamous cell carcinoma is not a common malignancy, its 
estimated incidence ranging between 3 and 5% of all gynecological malignancies, 
it seems that HPV infection plays a central role in its development; therefore, it is 
estimated that up to 70% of cases diagnosed with this malignancy present in fact 
HPV-related lesions [21, 22]. However, the rate of correlation between HPV infec-
tion and vulvar squamous cell carcinoma widely varies between different studies 
depending on the detection method and the included tumoral histopathological 
subtypes [23, 24].
Due to the fact that other related HPV infection malignancies (such as head or 
neck tumors) are associated with a significantly better outcome when compared 
to HPV-negative lesions, attention was focused on determining whether a similar 
relationship could be established between this type of infection and the overall 
survival in vulvar cancer patients. The improved outcome of patients diagnosed 
with HPV-related head or neck tumors seems to be explained especially through a 
better response to radiochemotherapy [23].
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However, scarce data have been reported so far. An interesting study conducted 
on this theme was published by Alonso et al. in Gynecologic Oncology Journal in 
2011 [23]. The study included 98 patients diagnosed with vulvar squamous cell 
carcinoma between 1995 and 2009 in which the authors studied the presence of 
HPV DNA; among these cases, 19 patients were diagnosed with HPV-associated 
infection, HPV-16 being the most prevalently detected subtype. Therefore, HPV-
16 subtype was reported in 14 cases, one of these cases presenting in the meantime 
HPV 56 co-infection; HPV-33 was found in two patients, whereas HPV-31, 51 and 
52 were each reported in 1 patient. When it comes to the clinical characteristics 
for the two subgroups, patients presenting with HPV-related tumors were signifi-
cantly younger when compared to those in whom the presence of the infection 
could not be demonstrated (68 years versus 78 years, p = 0.005). As for the other 
clinical factors that had been studied (such as FIGO stage at diagnostic, the median 
dimension of the tumor, association of ulceration, invasion depth and lymph node 
metastases) as well as for the type of performed therapeutic strategy (resection 
or radiochemotherapy), there was no significant difference between patients with 
HPV-related tumors when compared to those in whom HPV infection had not been 
observed [23].
The most relevant studies that focused on the correlation between HPV status 
and clinicopathological findings of patients with vulvar cancer are summarized in 
Table 1.
When it comes to the long-term outcomes, both disease-free and overall survival 
were significantly influenced by the FIGO stage at diagnosis, while the association 
of HPV infection showed no significant influence. Moreover, no significant dif-
ference was reported between the association of radiotherapy, HPV infection and 
overall survival; however, cases in which radiotherapy was associated reported a 
higher morbidity rate. In univariate analysis, the most important factors associat-
ing with the risk of disease progression and mortality were represented by the age 
over 78 years, FIGO stages III–IV, tumor size larger than 20 mm, ulceration, inva-
sion depth and the presence of lymph node metastases; however, in multivariate 














318 55 263 Patients’ age, smoking status, immune status, 
history of lichen sclerosus, diameter of the 
tumor, lympho-vascular space invasion, FIGO 
stage, risk of recurrence
Yap, 2018 [26] 40 14 26 Lower risk of recurrence
- No correlation between HPV status and age, TNM 
classification or type of treatment, disease-free 
survival interval, overall survival
Brinton, 2017 
[20]
370 — — Smoking, age, obesity
Rasmussen, 
2018 [27]




55 33 22 Patients’ age, smoking status, histopathological 
subtype
- No correlation between HPV status and FIGO 
stage, grade of the tumor, type of therapy
Table 1. 
Correlation between HPV status and clinicopathological findings in patients with vulvar cancer.
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analysis, only the association of lymph node metastases was still significantly 
associated with the mortality risk. When it comes to the influence of HPV infection, 
a significant association could not be seen even after adjusting for age. These data 
come to suggest that a supplementary mechanism might be involved in HPV-related 
vulvar neoplasms when compared to head and neck HPV-related neoplasms [23].
However, these results were not sustained by more recent studies conducted on 
the theme of the prognostic significance of HPV infection in patients diagnosed 
with vulvar squamous cell carcinoma and submitted to radiotherapy. In the article 
published by Lee in the same journal in 2016, contradictory results were found [29]. 
The study included 57 patients diagnosed with this pathological entity between 
1985 and 2011 in Brigham and Women’s Hospital and Dana Farber Cancer Institute 
who were treated with postoperative radiotherapy with radical intent or as part of 
the salvage setting. In all cases the presence of the following genotypes was stud-
ied: 6, 11, 16, 18, 26, 31, 33, 35, 40, 45, 51, 52, 56 and 59; similar to Alonso’s study, 
HPV-16 genotype was the most commonly encountered subtype. When it comes to 
the long-term outcomes, patients with p16-positive tumors reported a significantly 
better five-year progression-free and overall survival rates. Moreover, in univariate 
analysis, older age at diagnosis as well as higher FIGO stage and development of 
recurrent disease were associated with increased risk of progressive disease and 
mortality-related disease; however, association of chemotherapy did not signifi-
cantly impact on the overall survival. When a multivariate analysis was performed, 
the presence of p16 staining was associated with higher progression-free survival 
rates as well as with lower rates of recurrence [29]. The reported results of this study 
were similar to those regarding head and neck HPV-induced malignancies, the pres-
ence of HPV infection being associated with a better response to radiotherapy.
A recent study that was conducted by Hinten et al. that will be published in 
2018 in Gynecologic Oncology Journal demonstrated that in fact HPV-positive 
and negative vulvar cancer represent in fact two different pathologic entities with 
different localization and different prognosis. The study was conducted between 
March 1988 and January 2015 and included 318 patients. Among these cases, HPV-
related disease was reported in 55 cases, while the remaining 263 had non–HPV-
related vulvar neoplastic lesions [25]. The authors demonstrated that HPV-related 
lesions were more often localized on the perineum when compared to non-HPV 
lesions. When it comes to the long-term outcomes, the authors demonstrated that 
patients with HPV-induced lesions reported a better outcome in terms of both 
disease-free survival and overall survival when compared to non-HPV lesions; 
therefore, the 5-year and total disease-free survival were 76 versus 46%, and 28 
versus 13% in HPV-related lesions versus non–HPV-related lesions. In the mean-
time, the 5-year and total overall survival rates were 85 versus 57% in HPV-related 
lesions, and only 16% in non-HPV lesions. Another important prognostic factor 
that significantly influenced survival was the site of the lesions; therefore, even 
among patients with HPV-related lesions, cases presenting with perineal develop-
ment reported a significantly better prognosis when compared to nonperineal 
HPV-induced lesions; the difference remained significant in terms of both disease-
free and overall survival. Moreover, among patients presenting with perineal vulvar 
cancer, HPV-induced malignancies reported a more favorable outcome when com-
pared to non–HPV-induced lesions. In the meantime, disease-free survival was also 
significantly influenced by FIGO stage and diameter of the tumor, while the overall 
survival was significantly influenced by age at primary treatment, stage at diagno-
sis, tumor diameter and relapse as well as by the perineal localization of the lesions. 
Moreover, the 10-year survival rate was significantly influenced by age at the time 
of initial treatment, FIGO stage at diagnosis, tumoral diameter, p16 expression and 
perineal localization of the lesions. In terms of histopathological characteristics, 
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non–HPV-related lesions presented a larger diameter and were associated with a 
deeper invasion, more frequent metastases at the level of the lymphatic nodes and, 
therefore, a more frequent association of adjuvant radiotherapy. This different 
outcome could be explained by a more aggressive biological behavior of non–HPV-
related lesions as well as by the older age at diagnosis, elderly patients feeling most 
often ashamed to address to the gynecologist for such lesions [25]. All these data 
enabled the authors to conclude that most probably HPV and non–HPV-related 
lesions are in fact two different entities with different pathogenesis and different 
outcomes. Another possible explanation is related to the p53 status, non-HPV 
lesions being most commonly associated with a higher level of p53, and, in conse-
quence, with a more aggressive biology of the tumor [30].
Another recent study that focused on determining the prognostic significance 
of human papilloma virus and p16 expression in patients with vulvar squamous 
cell carcinoma submitted to radiotherapy was conducted by Yap et al. and has been 
recently published in Clinical Oncology Journal [26].
5. Factors influencing relapse in patients with premalignant or 
malignant diseases
Starting from the observation that patients with similar stages of disease who 
receive similar treatment strategies had a very different evolution, the researchers 
tried to identify the potential factors that influenced this evolution.
5.1 The influence of DNMT expression in development of recurrent vulvar 
cancer
DNMT (DNA methyltransferases), the enzyme that dictates and maintains DNA 
methylation patterns through the genome, seems to have significant differences in 
terms of expression in patients with vulvar carcinomas. Among the general name 
of DNMT, there are in fact three enzymes with various influences on the methyla-
tion process. DNMT1 is directly involved in the methylation process in normal 
cells; however, it seems that it plays a certain role in tumorigenesis too. DNMT3A 
and DNMT3B represent two other enzymes that present low expression levels in 
adult cells; however, these molecules seem to be overexpressed in several epithelial 
tumors [31, 32]. Moreover, their expression is associated with poor prognosis in 
patients with such epithelial tumors. A recent study conducted on this theme was 
published in Gynecologic Oncology Journal in 2016 and included patients treated 
for vulvar squamous cell carcinomas at the Pan Birmingham Gynecological Cancer 
Center between 2001 and 2008 [33]. The authors demonstrated the overexpres-
sion of DNMT1 in 83% of cases and of DNMT3A in 44% of cases, while the 
overexpression of DNMT3B was present in 42% of patients. After determining 
these parameters, the authors studied their influence on the risk of recurrence. 
DNMT3A was associated with a 4.5 fold increased risk of developing recurrent 
vulvar cancer; in multivariate analysis, the overexpression of this enzyme was 
also significantly correlated with a higher risk of local recurrence. Moreover, the 
authors tested the patients with overexpression of DNMT3A for CDKN2A, an 
indicator of HPV-induced dysplasia, and demonstrated that among patients with 
negative staining for CDKN2A, the overexpression of DNMT3A was significantly 
higher. Similar to DNMT3A, a higher level of DNMT3B was significantly associated 
with the risk of recurrence; however, the levels of this enzyme could not be cor-
related with CDKN2A expression. As for DNMT1 levels, there was no significant 
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correlation between this parameter and the risk of vulvar cancer recurrence; similar 
to DNMT3B, no significant correlation could be found between DNMT1 levels and 
CDKN2A expression [33].
5.2 The influence of pretreatment subtype of HPV on the risk of relapse in 
patients with VIN
Another interesting topic in regard to the influence of HPV on the overall prog-
nostic in patients with premalignant or malignant lesions is related to the effect of 
various viral subtypes on the long-term outcomes of these patients. A recent study 
conducted in Milan by Bogani et al. and published in 2017 in the European Journal 
of Obstetrics and Gynecology and Reproductive Biology included 64 patients diag-
nosed with high-grade VIN [34]. Among these cases, 41 patients had a previous his-
tory of HPV infection, the most commonly incriminated subtypes being HPV 16, 
18, 31 and 33. As for the performed procedures, most often it consisted of LASER 
ablation, excision or diathermocoagulation. After a mean follow-up of 56.7 months, 
10 patients were diagnosed with VIN2+ persistence or relapse, the mean disease-
free survival being 51.7 months; the authors demonstrated that a pretreatment 
infection with HPV 31 or HPV 33 subtype was associated with an increased risk of 
developing recurrent or persistent disease. Moreover, patients submitted to surgi-
cal excision followed by LASER ablation experienced a lower rate of relapse when 
compared with other types of therapies. These facts were explained through two 
mechanisms: the first one is related to the fact that HPV16, as well as HPV 31 and 
33, was associated with multifocal lesions, while multifocal lesions usually associate 
with a higher risk of persistent/recurrent disease; the second mechanism is prob-
ably related to the fact that HPV 31- and HPV33-induced lesions usually associate 
with a more rapid pattern of growth [34].
When it comes to the influence of HPV infection on the risk of recurrence of 
VIN, a recent study published by Satmary et al. in Gynecologic Oncology Journal 
in 2018 comes to demonstrate a significant relationship between these two enti-
ties [35]. The study included 784 patients with histopathological diagnostic of 
vulvar intraepithelial neoplasia which were treated with curative intent; how-
ever, 26,3% of cases developed recurrent intraepithelial neoplasia while 2,2% of 
these cases developed vulvar cancer. Among these cases, 25.9% of patients were 
40 years of age or less, 23.9% were aged between 41 and 50 years, 24.6% were 
aged between 51 and 60 years, while the remaining 25.6% of patients were aged 
over 60 years. As for the immunity status, immunosuppression was reported in 
189 cases and was caused by immune suppressant therapies (such as prednisone 
or methylprednisolone) in all but two patients (who were known to have HIV 
infection). When it comes to the performed therapy, it consisted of local excision 
in 54.8% of cases, laser therapy in 19.3% of cases and topical medication as single 
therapy or in association with excision or with laser in the remaining patients; 
in 17% of cases, data regarding therapy were not reported. However, cases in 
which the initial therapeutic option was not known were excluded from further 
study regarding recurrent disease. Among the 650 patients who benefited from 
any kind of treatment recurrence occurred in 171 cases, after a median disease-
free survival interval of 16.9 months, while the median follow-up period was 
89 months. Moreover, it seems that 75% of cases recurred within 43.1 months. 
When analyzed according to the age at the time of diagnosis, recurrence rate 
was significantly higher among patients over the age of 50 (p = 0.0031) when 
compared to younger patients. In univariate analysis, a significant association 
was also found between the risk of recurrence and the immunity system of the 
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patient, association of cervical intraepithelial neoplasia and increased BMI; in 
multivariate analysis, only age over 50 years, immunity status and association of 
cervical intraepithelial neoplasia were significantly associated with the risk of 
recurrence. When it comes to the influence of the type of treatment, in multi-
variate analysis, a trend toward a higher rate of recurrence was reported in cases 
submitted to nonexcisional therapies. As for the cases in which progression to 
vulvar cancer was encountered, the median time to progression to malignancy 
was 36.2 months. When studying only the patients who developed recurrences, 
the authors demonstrated that the relapse was significantly associated with 
increased age (patients over 50 years of age reporting a higher risk of recur-
rence), immunosuppression, positive resection margins and adjacent areas of 
lichen sclerosus or HPV infection [35].
5.3 The influence of TP53 gene on the risk of recurrence of vulvar cancer
Another factor that seems to influence the evolution of patients with vulvar 
cancer is represented by TP53 expression. Moreover, it has been widely demon-
strated that antitumor agents activating the TP53 tumor suppression gene can be 
safely used as adjuvant therapy for cases exhibiting this gene. When it comes to the 
association between HPV-related infection and TP53 expression, in cases diagnosed 
with head and neck malignancies, disruptive TP53 mutations were exclusively 
seen in HPV-negative tumors; moreover, these lesions were associated with poorer 
outcomes when compared with HPV-positive lesions [36].
6. The potential preventive role of HPV vaccination against HPV-
induced vulvar cancer
In order to diminish the risk of development of HPV-related malignancies, the 
quadrivalent and the two-valent HPV vaccines were approved to be used in both 
males and females in the European Union since 2006 and 2007, respectively [37, 38]. 
The main viral subtypes that are controlled by these two vaccines are HPV-16 and 
HPV-18, while the quadrivalent vaccine also contains proteins derived from HPV6 
and 11 [37]. Studies have demonstrated that using HPV vaccines in HPV-naïve 
persons protects against both benign and malignant conditions such as condylo-
mas, perineal and anal neoplasia in men as well as cervical cancer in women [38]. 
Therefore, routine HPV vaccination has been recommended in Europe in 12-year-old 
girls since 2009, in order to decrease the risk of development of such pathologies [39]. 
Due to the fact that there is a strong relationship between HPV infection and certain 
cases of vulvar cancer, a decreased incidence of this pathology is to be expected in the 
next decades, once the HPV vaccination has been widely implemented [40].
In order to maximize the protective effect of vaccination against HPV-related 
diseases, a nine-valent second generation of HPV vaccine was proposed; this nine-
valent HPV vaccine is expected to offer protection against the seven high-risk HPV 
subtypes (HPV 16/18/31/33/45/52/58) as well as against low-risk subtypes such as 
HPV 6/11. In this way, it is expected to provide a significant degree of protection 
against the main nine subtypes of HPV, which are responsible for up to 90% of all 
genital warts. The nine-valent vaccine proved to be effective in order to prevent 
97% of all high-grade premalignant lesions of cervix, vulva and vagina. In the study 
conducted by Hartwig et al. and published in 2015, which included all HPV-related 
malignancies reported in Europe in the year 2013, the authors demonstrated the 
efficacy of the second-generation HPV vaccine [2].
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7. Future perspectives
Once the benefits of vaccination in terms of prevention of HPV-related 
malignancies are widely demonstrated, another problem is reported, the one of 
the vaccine’s costs. It seems that, especially in the developing countries, where the 
incidence of HPV-related malignancies is higher, the accessibility to HPV vac-
cines is lower due to its price. Therefore, one of the future perspectives in regard 
to HPV-related diseases is lowering the price of the vaccine and increasing in this 
way the general accessibility to these products. Moreover, if we take into consid-
eration the fact that a significant number of women self-refer to the gynecologist 
when neoplastic disease is already present, it seems that an important future 
perspective should refer to the development of a vaccine that could also have a 
therapeutic role [41].
8. Conclusion
HPV infection seems to play a central role in developing premalignant or 
malignant vulvar lesions. Patients diagnosed with HPV-related lesions tend to have 
a younger age at diagnosis, especially due to the association with the presence of 
this virus. However, HPV-induced vulvar neoplastic lesions seem to have a better 
outcome in terms of both disease-free survival and overall survival when compared 
with non–HPV-related lesions. When it comes to the prevention of these lesions, it 
seems that anti-HPV vaccination might play a role; however, more studies are still 
needed in order to clearly state this aspect.
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